Tibet Duo Rui Pharmaceutical Co.,Ltd. completed the acquisition of 38.125% stake in Hubei Xinchengda Chemical Co., Ltd. from Wuhan Shengxiang Chemical Co., Ltd. and Wuhan Jinshengxing Automatic Control Engineering Co., Ltd.
September 19, 2023
Share
Tibet Duo Rui Pharmaceutical Co.,Ltd. (SZSE:301075) entered into a Investment Intent Agreement to acquire 38.125% stake in Hubei Xinchengda Chemical Co., Ltd. from Wuhan Shengxiang Chemical Co., Ltd. and Wuhan Jinshengxing Automatic Control Engineering Co., Ltd. for CNY 30.5 million on May 28, 2023. As of August 3, 2023 Tibet Duo Rui Pharmaceutical Co.,Ltd. entered into Investment Cooperation Agreement to acquire Hubei Xinchengda Chemical Co., Ltd. Hubei Xinchengda Chemical Co., Ltd. reported Total assets worth CNY 113.5 million, Total Common equity of CNY 74.8 million and Net loss of CNY 2.5 million in May 31, 2023. Transaction has already been approved by Tibet Duo Rui Pharmaceutical's Shareholders.
Tibet Duo Rui Pharmaceutical Co.,Ltd. (SZSE:301075) completed the acquisition of 38.125% stake in Hubei Xinchengda Chemical Co., Ltd. from Wuhan Shengxiang Chemical Co., Ltd. and Wuhan Jinshengxing Automatic Control Engineering Co., Ltd. on September 20, 2023.
Tibet Duo Rui Pharmaceutical Co Ltd is a company mainly engaged in the research and development (R&D), production and sales of chemical preparations and their active pharmaceutical ingredients (APIs). The Company's core product is sodium acetate ringer injection, which is mainly used to supplement body fluid, regulate electrolyte balance and correct acidosis. The Company's products also include its own products, compound electrolyte injection, compound mannitol injection and cefotaxime sodium for injection.
Tibet Duo Rui Pharmaceutical Co.,Ltd. completed the acquisition of 38.125% stake in Hubei Xinchengda Chemical Co., Ltd. from Wuhan Shengxiang Chemical Co., Ltd. and Wuhan Jinshengxing Automatic Control Engineering Co., Ltd.
TIBET DUO RUI PHARMACEUTICAL CO., LTD. 
